Biogen (BIIB) Accounts Payables (2009 - 2026)

Biogen has reported Accounts Payables for 18 years, with the latest figure at $403.9 million in Q2 2026.

• On a quarterly basis, Accounts Payables fell 1.1% year-over-year to $403.9 million in Q2 2026; TTM through Jun 2026 was $403.9 million, a 1.1% decrease from a year earlier, with the FY2025 full-year figure at $432.0 million, up 1.84% from the prior year.
• Accounts Payables was $403.9 million for Q2 2026 at Biogen, up from $358.5 million in the prior quarter.
• The five-year high for Accounts Payables was $491.5 million in Q4 2022, with the low at $354.5 million in Q2 2024.
• Average Accounts Payables over 5 years is $415.8 million, with a median of $410.8 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables climbed 23.2% in 2023, then declined 21.21% in 2024.
• Over 5 years, Accounts Payables stood at $491.5 million in 2022, then dropped by 17.95% to $403.3 million in 2023, then advanced by 5.18% to $424.2 million in 2024, then increased by 1.84% to $432.0 million in 2025, then fell by 6.5% to $403.9 million in 2026.
• The last three Accounts Payables figures came in at $403.9 million (Q2 2026), $358.5 million (Q1 2026), and $432.0 million (Q4 2025), per Business Quant data.